Table 2. Rates of each CST according to disease severity and HPV status/genotype – species level.
| CST I L. crispatusn/N (%) | CST II L. gasserin/N (%) | CST III L. inersn/N (%) | CST IV Mixedn/N (%) | CST V L. jenseniin/N (%) | TOTAL n/N (%) | |
|---|---|---|---|---|---|---|
| DISEASE SEVERITY (A) | ||||||
| Normal | 10/20 (50) | 0/20 (0) | 8/20 (40) | 2/20 (10) | 0/20 (0) | 20/20 (100) |
| LSIL | 22/52 (42) | 1/52 (2) | 12/52 (23) | 11/52 (21) | 6/52 (12) | 52/52 (100) |
| HSIL | 37/92 (40) | 3/92 (3) | 27/92 (29) | 25/92 (27) | 0/92 (0) | 92/92 (100) |
| Cancer | 1/5 (20) | 1/5 (20) | 0/5 (0) | 2/5 (40) | 1/5 (20) | 5/55 (100) |
| Total | 70/169 (41) | 5/169 (3) | 47/169 (28) | 40/169 (24) | 7/169 (4) | 169/169 (100) |
| P value1 | 0.30 | 0.12 | 0.38 | 0.06 | 0.47 | – |
| Q value1 | 0.47 | 0.46 | 0.47 | 0.32 | 0.47 | – |
| DISEASE SEVERITY (B) (ASCUS/LSIL separate)2 | ||||||
| Normal | 10/20 (50) | 0/20 (0) | 8/20 (40) | 2/20 (10) | 0/20 (0) | 20/20 (100) |
| ASCUS | 16/26 (62) | 0/26 (0) | 4/26 (15) | 5/26 (19) | 1/26 (4) | 26/26 (100) |
| LSIL | 6/26 (23) | 1/26 (4) | 8/26 (31) | 6/26 (23) | 5/26 (19) | 26/26 (100) |
| HSIL | 37/92 (40) | 3/92 (3) | 27/92 (29) | 25/92 (27) | 0/92 (0) | 92/92 (100) |
| Cancer | 1/5 (20) | 1/5 (20) | 0/5 (0) | 2/5 (40) | 1/5 (20) | 5/5 (100) |
| Total | 70/169 (41) | 5/169 (3) | 47/169 (28) | 40/169 (24) | 7/169 (4) | 169/169 (100) |
| P value1 | 0.10 | 0.11 | 0.65 | 0.06 | 0.87 | – |
| Q value1 | 0.33 | 0.33 | 0.87 | 0.32 | 0.87 | – |
| HPV STATUS | ||||||
| Negative | 13/24 (54) | 0/24 (0) | 6/24 (25) | 5/24 (21) | 0/24 (0) | 24/24 (100) |
| Positive | 38/93 (41) | 2/93 (2) | 25/93 (27) | 26/93 (28) | 2/93 (2) | 93/93 (100) |
| Total | 51/117 (44) | 2/117 (2) | 31/117 (26) | 31/117 (26) | 2/117 (2) | 117/117 (100) |
| P value3 | 0.26 | 1.00 | 1.00 | 0.61 | 1.00 | – |
| Q value3 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | – |
| HPV GENOTYPE | ||||||
| HPV-16 | 13/31 (42) | 1/31 (3) | 8/31 (26) | 9/31 (29) | 0/31 (0) | 31/31 (100) |
| HPV-18 | 3/5 (60) | 0/5 (0) | 1/5 (20) | 1/5 (20) | 0/5 (0) | 5/5 (100) |
| Other HR-HPV subtype | 12/26 (46) | 1/26 (4) | 7/26 (27) | 5/26 (19) | 1/26 (4) | 26/26 (100) |
| Total | 28/62 (45) | 2/62 (3) | 16/62 (26) | 15/62 (24) | 1/62 (1) | 62/62 (100) |
| P value3 | 0.74 | 1.00 | 1.00 | 0.81 | 0.50 | – |
| Q value3 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | – |
| DISEASE SEVERITY and HPV STATUS | ||||||
| Normal/LSIL, HPV neg | 11/20 (55) | 0/20 (0) | 6/20 (30) | 3/20 (15) | 0/20 (0) | 20/20 (100) |
| Normal/LSIL, HPV pos | 17/34 (50) | 0/34 (0) | 7/34 (21) | 7/34 (21) | 3/34 (8) | 334/4 (100) |
| HSIL, HPV pos | 21/58 (36) | 2/58 (3) | 16/58 (28) | 19/58 (33) | 0/58 (0) | 58/58 (100) |
| Cancer | 1/5 (20) | 1/5 (20) | 0/5 (0) | 2/5 (40) | 1/5 (20) | 5/5 (100) |
| Total | 52/117 (44) | 3/117 (3) | 29/117 (24) | 31/117 (26) | 3/117 (3) | 117/117 (100) |
| P value1 | 0.08 | 0.05 | 0.69 | 0.15 | 0.57 | – |
| Q value1 | 0.34 | 0.24 | 0.69 | 0.46 | 0.69 | – |
ASCUS: atypical squamous cells of undetermined significance; CST: Community state type; CST I = Lactobacillus crispatus-dominant; CST II = Lactobacillus gasseri-dominant; CST III = Lactobacillus iners-dominant, CST IV = high-diversity, Lactobacillus spp-deplete; CST V = Lactobacillus jensenii-dominant; HPV: Human Papilloma Virus; HPV neg: HPV negative; HPV pos: HPV positive; HR-HPV: High-risk Human Papilloma Virus; HSIL: High-grade Squamous intraepithelial lesion; LSIL: Low-grade squamous intraepithelial lesion.
1P-value & Q-value calculated using linear regression.
2ASCUS and LSIL are split in two separate groups.
3P-value calculated using Fishers exact test, Q-value calculated using Benjamini-Hochberg false discovery rate (FDR) method.